Introduction: Until recently, patients with locally advanced or metastatic urothelial carcinoma after progression on cisplatin-containing chemotherapy had limited systemic treatment options with no significant survival benefit and poor tolerability. Advances in the field of immunotherapy with the introduction of checkpoint inhibitors have led to paradigm shifts in the treatment of various malignancies.Areas covered: The current review will summarize the clinical evidence of checkpoint inhibitors in bladder cancer, with a focus on pembrolizumab.Expert commentary: Category 1 evidence indicates that the checkpoint inhibitor pembrolizumab improves overall survival in patients with locally advanced or metastatic urothelial carcinoma who progress...
Junichi Inokuchi, Masatoshi EtoDepartment of Urology, Graduate School of Medical Sciences, Kyushu Un...
Immune checkpoint inhibitors have revolutionized the treatment of bladder urothelial cancers and hav...
Immune-checkpoint inhibitors blocking the programmed death 1/programmed death-ligand 1 (PD-1/PD-L1) ...
BACKGROUND: Bladder cancer is the fifth most common cancer in the United States. Cisplatin-based che...
For many decades, no significant improvements could be achieved to prolong the survival in metastati...
The treatment of advanced urothelial carcinoma (UC) has dramatically changed with the advent of immu...
The treatment of advanced metastatic urothelial carcinoma has recently evolved with the approval of ...
BACKGROUND: Patients with advanced urothelial carcinoma that progresses after platinum-based chemoth...
Introduction: Immunotherapy is changing the way we think about and treat urothelial carcinoma (UC). ...
Bladder cancer (BC) is the most common malignancy of the genitourinary tract, with high morbidity an...
Important advances in the understanding of the biology and mechanisms of tumor progression of urothe...
International audiencePURPOSE:Over the past 3 decades, no major treatment breakthrough has been repo...
Brian Dietrich,1 Sandy Srinivas2 1Department of Hematology/Oncology, Stanford University School of M...
Dharmesh Gopalakrishnan,1 Vadim S Koshkin,2 Moshe C Ornstein,2 Athanasios Papatsoris,3 Petros Grivas...
Funding Information: Supported by the National Cancer Institute of the National Institutes of Health...
Junichi Inokuchi, Masatoshi EtoDepartment of Urology, Graduate School of Medical Sciences, Kyushu Un...
Immune checkpoint inhibitors have revolutionized the treatment of bladder urothelial cancers and hav...
Immune-checkpoint inhibitors blocking the programmed death 1/programmed death-ligand 1 (PD-1/PD-L1) ...
BACKGROUND: Bladder cancer is the fifth most common cancer in the United States. Cisplatin-based che...
For many decades, no significant improvements could be achieved to prolong the survival in metastati...
The treatment of advanced urothelial carcinoma (UC) has dramatically changed with the advent of immu...
The treatment of advanced metastatic urothelial carcinoma has recently evolved with the approval of ...
BACKGROUND: Patients with advanced urothelial carcinoma that progresses after platinum-based chemoth...
Introduction: Immunotherapy is changing the way we think about and treat urothelial carcinoma (UC). ...
Bladder cancer (BC) is the most common malignancy of the genitourinary tract, with high morbidity an...
Important advances in the understanding of the biology and mechanisms of tumor progression of urothe...
International audiencePURPOSE:Over the past 3 decades, no major treatment breakthrough has been repo...
Brian Dietrich,1 Sandy Srinivas2 1Department of Hematology/Oncology, Stanford University School of M...
Dharmesh Gopalakrishnan,1 Vadim S Koshkin,2 Moshe C Ornstein,2 Athanasios Papatsoris,3 Petros Grivas...
Funding Information: Supported by the National Cancer Institute of the National Institutes of Health...
Junichi Inokuchi, Masatoshi EtoDepartment of Urology, Graduate School of Medical Sciences, Kyushu Un...
Immune checkpoint inhibitors have revolutionized the treatment of bladder urothelial cancers and hav...
Immune-checkpoint inhibitors blocking the programmed death 1/programmed death-ligand 1 (PD-1/PD-L1) ...